{"id":669386,"date":"2026-05-14T01:18:07","date_gmt":"2026-05-14T01:18:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/669386\/"},"modified":"2026-05-14T01:18:07","modified_gmt":"2026-05-14T01:18:07","slug":"are-these-2-battered-asx-healthcare-shares-too-cheap-to-ignore","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/669386\/","title":{"rendered":"Are these 2 battered ASX healthcare shares too cheap to ignore?"},"content":{"rendered":"\n

Some ASX healthcare shares are going through a brutal period as competition, weaker demand and broader market pressures hammer investor confidence.<\/p>\n

CSL Ltd (ASX: CSL<\/a>) has dominated headlines recently for all the wrong reasons, but other ASX healthcare shares are also suffering heavy losses.<\/p>\n

Shares in Cochlear Ltd (ASX: COH<\/a>) are down roughly 63% over the past 12 months, while Telix Pharmaceuticals Ltd (ASX: TLX<\/a>) has fallen around 44%.<\/p>\n

So, have these ASX healthcare shares<\/a> become too cheap to ignore?<\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

Cochlear <\/p>\n

Cochlear’s collapse accelerated after a disappointing trading update<\/a> released on 22 April.<\/p>\n

The ASX healthcare share plunged from around $168 to near $90 within days. That’s an extraordinary 46% wipeout for a blue-chip healthcare company.<\/p>\n

Although the share price has since stabilised somewhat, the damage remains severe. The company, which controls roughly 50% of the global cochlear implant market, sharply downgraded FY26 underlying net profit guidance to between $290 million and $330 million. That was a major cut from its previous guidance range of $435 million to $460 million.<\/p>\n

Management blamed weaker hearing implant demand across developed markets, slower referrals, postponed surgeries and disruptions in the Middle East that caused cancelled orders and delivery delays.<\/p>\n

For a company long viewed as one of the ASX’s most reliable healthcare performers, the downgrade badly rattled investor confidence.<\/p>\n

Still, the long-term investment case may not be broken. Cochlear remains the global leader in implantable hearing technology and continues reinvesting heavily into research and development, allocating around 13% of revenue toward innovation.<\/p>\n

The company also benefits from ageing populations and a growing pool of patients with hearing loss worldwide. That suggests current weakness may prove more cyclical than structural.<\/p>\n

Analyst opinion remains sharply divided. Jarden currently has a $169 price target on the ASX healthcare share, implying upside of almost 70%.<\/p>\n

However, Macquarie recently slashed its target from $239 to $115, while Morgans maintains a hold rating and a $107.17 target.<\/p>\n

Telix Pharmaceuticals <\/p>\n

Telix shares have also experienced wild volatility<\/a>. The ASX healthcare stock is down around 8% over the past month, remains up roughly 30% year to date, but has still slumped approximately 43% over 12 months.<\/p>\n

Unlike many biotech companies, Telix already generates commercial revenue. Its lead product, Illuccix, is producing growing sales in the US market and provides a genuine commercial foundation for the business.<\/p>\n

Telix operates in the rapidly expanding radiopharmaceuticals sector, developing imaging and therapeutic products for cancer treatment.<\/p>\n

The company also has a growing development pipeline targeting kidney cancer, brain cancer and other oncology opportunities.<\/p>\n

That helps explain the extreme share price swings. Positive announcements often trigger sharp rallies, while broader biotech weakness or slower news flow can spark aggressive pullbacks.<\/p>\n

Despite the volatility, analysts remain overwhelmingly bullish on the ASX healthcare share. According to TradingView data, all 16 brokers covering Telix shares currently rate the ASX healthcare stock as either a buy or strong buy.<\/p>\n

The average price target sits at $24.22, implying roughly 65% upside from current levels. The most bullish analyst target stands near $31. That points to a potential upside of approximately 110% if Telix continues delivering operational growth.<\/p>\n","protected":false},"excerpt":{"rendered":"Some ASX healthcare shares are going through a brutal period as competition, weaker demand and broader market pressures…\n","protected":false},"author":2,"featured_media":669387,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-669386","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/669386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=669386"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/669386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/669387"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=669386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=669386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=669386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}